Needless Vaccination in Paediatric population age 12yr to 18yr by ZYCOV- D By DR BHARGAVI BADE

Cadila Healthcare Limited, India developed a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. (S) protein, following immunization with three doses adminis- tered 28 days apart. Neutralizing antibody response was also demonstrated against wild type SARS-CoV-2 strain, which may play a substantial role in viral clearance and mitigation of human clinical disease. Implications of all the available evidence Many vaccine candi- dates are in rapid development, including recombinant-protein based vaccines, replicating or non-replicating viral vector- based vaccines, DNA vaccines, and mRNA vaccines (which mostly have focused on the spike glycoprotein or receptor binding domain), live attenuated vaccines, and inactivated virus vaccines. Our findings indicate that DNA vaccine is safe and immunogenic in healthy adults. ZyCoV-D® vaccination course consists of three separate doses of 0.2 ml each. ZyCoV-D® vaccination schedule consists of 3 separate doses of 2 mg each to be given at an interval of 28 days each (day 0, day 28 and day 56).

Each 2 mg dose consists of two shots of 0.1ml each given by needle free injector (Pharmajet Tropis device) via intradermal route at two separate sites (preferably deltoid region of both the arms). Special warnings and precautions for use Hypersensitivity As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Concurrent Illness As with other vaccines, administration of ZyCoV-D® should be postponed in individuals suffering from an acute severe febrile illness. However, the presence of a minor infection, such as cold, and/or low grade fever should not delay vaccination. Immunocompromised individuals It is not known whether individuals with impaired immune responsiveness, including individuals receiving immunosuppressant therapy, will elicit the same response as immunocompetent individuals to the vaccine regimen. Immunocompromised individuals may have relatively weaker immune response to the vaccine regimen. Common side effects Injection site redness Injection site pain Injection site itching Injection site swelling Fever Muscle Pain Headache Nausea Fatigue / Tiredness Diarrhea